The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Totally agree Jatw. I came across similar situation twice, few years ago, when two stocks in my portfolio were delisted from LSE and migrated to NYSE. My stockbroker wasn’t dealing with foreign listed companies and hence, ‘recommended’ an European broker instead. Similar situation could happen if HCM moves out completely from LSE. Best option would be for the company to move out of AIM market and get listed on the main LSE market. It will be good for the UK investors and at the same time, can attract investors from China (?and HK) to invest in LSE listed HCM shares using the London-Shanghai link. I wonder why the financial analysts don’t ask the CEO about this during the so called ‘discussion sessions’.
Thankyou amones, I had forgotten about the Shanghai -London Stock Connect, maybe Chi-Med would consider moving to a Main Listing in order to take advantage of this system, allowing Chinese Investors access, although if the HK listing is back on maybe that would not be a priority.
We have to be careful what we wish for.....eg Verona is delisting from AIM and will be solely traded on NASDAQ. I know this is a different situation for a much smaller company....but I for one would not want to lose a London listing for HCM.
A company with ambition to be a global $20bn company should afford global premium listings.
If the ‘London-Shanghai stock markets link’ works out well, it shall not only helps to get an uplift in sp but also the much needed funding, without having to list at HK.
(It might not be as simple as this, but few other posters had mentioned these benefits on this discussion forum, months ago)
Nice to read your posts after brief hiatus, Davey.
Although your opinion is fair enough about HCM moving to the main LSE market, couple of benefits that have been discussed here in the recent past;
1. fund managers who are not able invest in AIM listed companies, can add HCM on their wish list. That might boost the sp significantly.
2. ‘London-Shanghai stock link’ - allows private and institutional investors based in China and HK to invest in LSE listed HCM. (again, AIM listed stocks excluded at present). That can bring in significant interest.
These two reasons should be good enough for the company to try.
agree about the HK listing, there has been a swathe of Biotechs listing there in 2020, and most have been very successful
amones, an interesting and one that I have had a habit of asking at AGM's over the past few years. My understanding is that Company doesn't see any particular advantages of leaving AIM or disadvantages of remaining on it . I suspect the focus has been on the U.S Specialist Investor ecosystem which is of course the largest of its type. I've also deduced and concluded that the Company still sees a London listing as an important stabilising effect, and serves the small number of long term loyal Investors in the UK.
Personally I see the London market as an irrelevance from a Biopharma perspective, largely because of a lack of specialist Biotech Investors and Funds.
I keep repeating this. Is the company making any efforts to move out of AIM and get listed on main market of LSE? Pharma companies are generally doing well and the same could be expected of HCM. Its deep pipeline and its efficient management will be enough to get the attention of bigger funds.
Why the delay ?
For all the problems of the last year or so, you have to love this company.
It is doing good work that will benefit many thousands of patients.
It is one for the future and hence current global difficulties have limited effect.
I suspect CKHH will want to place 10-15% in a HK IPO - and HCM will raise further funds at the same time as long as their GA agreement permits (no restriction was mentioned so I assume they can). Market conditions are turning, but have been good for drug developers recently. They should get on with it before markets change.
Got to wonder if not news of a deal or HK IPO not on its way .